Form 4: Silo Pharma CEO Weisblum Boosts Stake with Share Purchases

Sentiment:

Insider Transaction Report 21 November 2025 6:35 PM

Silo Pharma CEO Eric Weisblum increased his direct ownership in the company by purchasing 2,000 shares of common stock over two days in November 2025.

Summary

Eric Weisblum, the Chief Executive Officer and a Director of Silo Pharma, Inc. (SILO), acquired additional shares of the company's common stock.
On November 20, 2025, Weisblum purchased 1,000 shares of common stock at a price of $0.37 per share.
On November 21, 2025, he acquired another 1,000 shares of common stock at a price of $0.365 per share.
Following these transactions, Weisblum directly beneficially owns a total of 211,932 shares of Silo Pharma common stock.

Sentiment

Score: 7

Explanation: The CEO's purchase of additional shares indicates confidence in the company's prospects, which is generally viewed positively by the market, though the transaction size is relatively small.

Positives

CEO Eric Weisblum increased his direct beneficial ownership in Silo Pharma, indicating confidence in the company's future prospects.
The acquisition of 2,000 shares through open market purchases demonstrates a personal investment by a key executive at current market prices.

Future Outlook

Industry Context

Related Party Transactions

Eric Weisblum, the Chief Executive Officer and Director of Silo Pharma, Inc., acquired 2,000 shares of the company's common stock through open market purchases on November 20 and 21, 2025.

Stakeholder Impact

Shareholders: May view the insider buying as a positive signal of management confidence, potentially influencing investor sentiment.

Key Dates

Date	Description
11/20/2025	Transaction Date Acquisition of 1,000 shares of Common Stock by Eric Weisblum.
11/21/2025	Transaction Date Acquisition of 1,000 shares of Common Stock by Eric Weisblum.
11/21/2025	Signature Date of Reporting Person, Eric Weisblum.

Recommendation

hold

The CEO's direct purchase of shares, while a positive signal of confidence, is a relatively small transaction and does not fundamentally alter the company's financial position or strategic outlook. It reinforces a 'hold' position for existing investors, suggesting management believes in the current valuation and future potential, but doesn't present a compelling reason for a 'buy' or 'sell' based solely on this filing.

Keywords

Silo Pharma, SILO, Eric Weisblum, insider trading, stock purchase, common stock, CEO, director, Form 4

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.